Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

NOMA vs ABCL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABCL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

ABCL Overall Winner 6-Pillar Tally: NOMA 1 – 4 ABCL (1 Tie) Matrix Metrics: NOMA 3 – 7 ABCL

As of Nov 19, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over NOMA (NOMA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). NOMA carries a Unified Composite Score of 49.5/100 (HOLD) at $1.10 (N/M Forward P/E, -164.5% operating margin), whereas ABCL carries 58.6/100 (HOLD) at $10.47 (27.6x Forward P/E, -298.0% operating margin).

  • Growth vs. Quality Trade-Off: ABCL earns the overall head-to-head edge with a stronger Unified Composite Score (58.6/100 HOLD vs. NOMA 49.5/100 HOLD) and 2.30β · 85% Vol risk profile, whereas NOMA leads top-line expansion (+122.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: NOMA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile ABCL is in a Breakdown options structure phase (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NOMA vs ABCL
NOMA US Equity
NOMA
Institutional Equity
$1.10
-9.84% 1D
Market Cap $22.3M
TTM Revenue $2.0M
Forward P/E N/M
Beta / 30D Vol -0.45β · 156% Vol
Unified Composite Score
49.5 / 100 HOLD
Tech 65.0 Fund 61.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.9%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $1.30 · SMA50: $1.47
ABCL NASDAQ Head-to-Head Winner
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$10.47
-4.99% 1D
Market Cap $3.6B
TTM Revenue $68M
Forward P/E 27.6x
Beta / 30D Vol 2.30β · 85% Vol
Unified Composite Score
58.6 / 100 HOLD
Tech 36.0 Fund 59.0 Flow 70.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 38.4 · SMA20: $11.90 · SMA50: $12.32

6-Pillar Scorecard Institutional Category Breakdown (NOMA 1 – 4 ABCL)

Columns: Metric · NOMA · ABCL
1. Valuation Multiples ABCL
Forward P/E N/M 27.6x
Trailing P/E N/M 27.6x
PEG Ratio N/M N/M
EV / Revenue 11.4x 52.6x
2. Growth & Scale ABCL
Revenue Growth (YoY) +122.9% +18.8%
Earnings Growth (YoY) +0.0% +45.9%
TTM Revenue (USD) $2.0M $68M
Market Cap $22.3M $3.6B
3. Profitability & Quality NOMA
Gross Margin 71.4% N/A
Operating Margin -164.5% -298.0%
Net Profit Margin -213.9% -218.6%
Return on Equity (ROE) -40.7% -14.6%
4. Balance Sheet & Cash Flow ABCL
Cash Generation (TTM) N/A -$33M
Cash Flow Margin N/A -48.4%
Net Cash / Leverage $0.84 Book/Sh · -40.7% ROE $30M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABCL
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile N/A (N/A) 80.5% (24th %ile)
Put/Call OI Skew N/A 0.25x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Leisure Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NOMA (3) vs ABCL (7)
Institutional Metric NOMA ABCL Criterion Row Edge
Market Capitalization
Scale
$22.3M $3.6B Larger Scale ABCL
Trailing P/E Ratio
Valuation
N/M 27.6x Lower Multiple ABCL
Forward P/E Ratio
Valuation
N/M 27.6x Lower Multiple ABCL
Revenue Growth (YoY)
Growth
+122.9% +18.8% Higher Growth NOMA
Operating Margin (TTM)
Profitability
-164.5% -298.0% Higher Margin NOMA
Net Profit Margin
Profitability
-213.9% -218.6% Higher Margin NOMA
Return on Equity (ROE)
Capital Efficiency
-40.7% -14.6% Higher ROE ABCL
52-Week Range Position
Momentum
3% ($1–$10) 63% ($3–$15) Stronger Trend ABCL
Beta / 30D Volatility
Risk Regime
-0.45β · 156% Vol 2.30β · 85% Vol Lower Realized Risk ABCL
Unified Institutional Score
Composite Signal
49.5 / 100 (HOLD) 58.6 / 100 (HOLD) Higher Composite ABCL
Trailing 12M Revenue (USD)
Operating Scale
$2.0M $68M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 11.4x EV/Rev N/M PEG · 52.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($0.84 Book/Sh · -40.7% ROE) -$33M ($30M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABCL +14.11 pp
NOMA: -28.57% · ABCL: -14.46%
3M Horizon ABCL +45.68 pp
NOMA: -53.19% · ABCL: -7.51%
6M Horizon ABCL +172.27 pp
NOMA: -68.57% · ABCL: +103.7%
1Y Horizon ABCL +274.05 pp
NOMA: -87.98% · ABCL: +186.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NOMA vs ABCL. Trailing 12-month operating profitability (NOMA -164.5% vs ABCL -298.0%) and valuation multiples (NOMA N/M vs ABCL 27.6x Forward P/E) are benchmarked directly in Pillar 4 below.

NOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.0M
Gross Margin71.4%
Op. Margin-164.5%
ROE / Fwd P/E-40.7% · N/M
ABCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$68M
Gross MarginN/A
Op. Margin-298.0%
ROE / Fwd P/E-14.6% · 27.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NOMA BREAKDOWN
31d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact NOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABCL BREAKDOWN
37d in phase · OBV DISTRIBUTION
Current IV 80.5%
IV Percentile 24th %ile
Put/Call OI Skew 0.25x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ABCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $11.12 · IV 84.0%

ABCL Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,112)

Compare $1,112 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 84.0% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $12 / $13 Bull Call Spread

Buy 4x $12C · Sell 4x $13C · 32d

Net Entry $80 Debit
T+5d @ +5% Move +$25 (+31%)
Max Risk / Buffer $80 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Jan 15 '27 $10 / $9 Bull Put Spread

Sell 5x $10P · Buy 5x $9P · 60d

Net Entry $175 Credit
Max Credit / Yield +$175 (+53.8% RoM)
Max Risk / Buffer -13.2% Cushion ($325 Mgn)
5d Edge & Liquidity 70% PoP · Liq A
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $12 / $10 Bear Put Spread

Buy 1x $12P · Sell 1x $10P · 32d

Net Entry $106 Debit
T+5d @ -5% Drop +$16 (+15%)
Max Risk / Buffer $106 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NOMA Moat Profile Cyclical / Execution-Driven Positioning
Leisure Operator
Competes within the Leisure value chain with $22.3M market capitalization and -164.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABCL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6B market capitalization and -298.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NOMA vs ABCL Key Questions & Quantitative Answers

As of Nov 19, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over NOMA (NOMA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). NOMA carries a Unified Composite Score of 49.5/100 (HOLD) at $1.10 (N/M Forward P/E, -164.5% operating margin), whereas ABCL carries 58.6/100 (HOLD) at $10.47 (27.6x Forward P/E, -298.0% operating margin). Growth vs. Quality Trade-Off: ABCL earns the overall head-to-head edge with a stronger Unified Composite Score (58.6/100 HOLD vs. NOMA 49.5/100 HOLD) and 2.30β · 85% Vol risk profile, whereas NOMA leads top-line expansion (+122.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NOMA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile ABCL is in a Breakdown options structure phase (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABCL leads the Growth & Scale pillar: NOMA posts +122.9% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (71.4% gross margin, -164.5% operating margin), compared with ABCL at +18.8% YoY revenue growth and +45.9% YoY earnings growth on $68M TTM revenue (N/A gross margin, -298.0% operating margin). On trailing 12-month operating scale, NOMA generates $2.0M in USD-normalized revenue versus $68M for ABCL. In operating R&D and SG&A reinvestment, NOMA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABCL.

ABCL screens cheaper on headline valuation multiples. NOMA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 11.4x EV/Revenue (unreported cash flow margin), whereas ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 52.6x EV/Revenue (-48.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NOMA (-40.7% ROE) versus ABCL (-14.6% ROE) capital efficiency.

In options market volatility and institutional positioning, NOMA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (-0.45β · 156% Vol realized risk). By comparison, ABCL carries 80.5% implied volatility (24th %ile, Compressed (<25th %ile)), a 0.25x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.